Mirae Asset Global Investments Co. Ltd. Purchases New Position in Natera, Inc. $NTRA

Mirae Asset Global Investments Co. Ltd. purchased a new stake in Natera, Inc. (NASDAQ:NTRA) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 18,255 shares of the medical research company’s stock, valued at approximately $7,545,000.

A number of other hedge funds also recently made changes to their positions in the business. Profund Advisors LLC raised its stake in Natera by 5.6% during the 3rd quarter. Profund Advisors LLC now owns 6,553 shares of the medical research company’s stock valued at $2,708,000 after acquiring an additional 348 shares in the last quarter. Vise Technologies Inc. boosted its position in Natera by 5.3% during the 3rd quarter. Vise Technologies Inc. now owns 2,010 shares of the medical research company’s stock worth $831,000 after acquiring an additional 101 shares during the period. Americana Partners LLC bought a new position in shares of Natera in the third quarter worth $203,000. LJI Wealth Management LLC bought a new position in shares of Natera in the third quarter worth $207,000. Finally, Canopy Partners LLC acquired a new position in shares of Natera during the third quarter valued at $211,000. Institutional investors own 99.90% of the company’s stock.

Natera Trading Up 0.6%

Shares of NTRA stock opened at $391.03 on Thursday. Natera, Inc. has a 1 year low of $181.00 and a 1 year high of $437.41. The business’s fifty day moving average is $380.30 and its 200-day moving average is $268.64.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The business had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. During the same quarter in the prior year, the firm posted ($0.74) earnings per share. The company’s revenue was up 37.7% on a year-over-year basis. As a group, sell-side analysts expect that Natera, Inc. will post -1.14 earnings per share for the current fiscal year.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Medicare coverage for Signatera in HCC could improve patient access and support adoption of Natera’s cancer-monitoring tests. The coverage milestone adds to the commercial opportunity for its oncology business. Natera Medicare coverage for Signatera in HCC
• Positive Sentiment: New ESMO oncology evidence was described as broadening the case for Natera’s cancer-testing portfolio, potentially reinforcing the longer-term growth story. ESMO data broaden Natera’s oncology case
• Neutral Sentiment: Natera was expected to report earnings on November 5, making results and management’s outlook a near-term catalyst; the preview article did not provide reported results. Natera earnings preview
• Neutral Sentiment: The reported analyst consensus price target was $394.31, close to the share price cited in the provided market background, suggesting limited implied upside from that target alone. Natera consensus target price
• Neutral Sentiment: CFO Michael Brophy sold 1,178 shares under a pre-arranged Rule 10b5-1 plan and retained 48,480 shares. The scheduled nature and relatively small size of the sale may temper its significance as a signal about management’s outlook. CFO share sale report

Insider Transactions at Natera

In other Natera news, insider Solomon Moshkevich sold 15,160 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $326.89, for a total value of $4,955,652.40. Following the completion of the sale, the insider directly owned 110,859 shares of the company’s stock, valued at approximately $36,238,698.51. This represents a 12.03% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Chapman sold 3,801 shares of the firm’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $411.80, for a total transaction of $1,565,251.80. Following the transaction, the chief executive officer owned 87,431 shares of the company’s stock, valued at approximately $36,004,085.80. This trade represents a 4.17% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 53,573 shares of company stock valued at $19,856,400 in the last three months. 5.05% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

NTRA has been the topic of a number of recent analyst reports. Zacks Research cut shares of Natera from a “hold” rating to a “strong sell” rating in a research note on Friday, October 16th. Barclays increased their target price on shares of Natera from $340.00 to $475.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Guggenheim raised their target price on shares of Natera from $360.00 to $475.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Roth Capital initiated coverage on shares of Natera in a research report on Thursday, October 22nd. They set a “buy” rating and a $475.00 price target on the stock. Finally, Morgan Stanley upped their price target on shares of Natera from $355.00 to $435.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $394.31.

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.